The European internet-based patient and research database for primary immunodeficiencies: Results 2006-2008

B. Gathmann, B. Grimbacher, J. Beauté, Y. Dudoit, N. Mahlaoui, A. Fischer, V. Knerr, G. Kindle, R. Micol, L. Benslama, A. Plebani, L. Notarangelo, C. Pignata, C. Bangs, M. Lucas, P. Tierney, C. Core, J. Dempster, A. Exley, D. KumararatneO. Paschenko, I. Kondratenko, Anna Shcherbina, S. Velbri, P. Ciznar, R. Duobiene, S. Kilic, N. Kütükcüler, Ö Sanal, I. Reisli, O. Yegin, M. Kanariou, E. Papadopoulou-Alataki, M. Trachana, M. Hatzistilianou, C. M. Farber, I. Meyts, S. Pasic, D. Richter, L. Máródi, I. Touitou, M. Abuzakouk, C. Feighery, V. Thon, J. Litzman, M. Cucuruz, B. Wolska, A. Szaflarska, S. Reda, P. Soler, I. Caragol, P. Llobet, I. Savchak, L. Marques, A. Koren, M. Hörnes, S. Shchebet, S. Goldacker, H. Ritterbusch, M. Faßhauer, F. Sollinger, T. Witte, U. Baumann, H. Wittkowski, D. Viemann, T. Niehues, H. Stimm, N. Brodszki

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Summary Primary immunodeficiencies (PID) are rare diseases; therefore transnational studies are essential to maximize the scientific outcome and to improve diagnosis and therapy. In order to estimate the prevalence of PID in Europe as well as to establish and evaluate harmonized guidelines for the diagnosis and treatment of PID, the European Society for Immunodeficiencies (ESID) has developed an internet-based database for clinical and research data on patients with PID. This database is a platform for epidemiological analyses as well as the development of new diagnostic and therapeutic strategies and the identification of novel disease-associated genes. Within 4 years, 7430 patients from 39 countries have been documented in the ESID database. Common variable immunodeficiency (CVID) represents the most common entity, with 1540 patients or 20·7% of all entries, followed by isolated immunoglobulin (Ig)G subclass deficiency (546 patients, 7·4%). Evaluations show that the average life expectancy for PID patients varies from 1 to 49 years (median), depending on the type of PID. The prevalence and incidence of PID remains a key question to be answered. As the registration progress is far from finished we can only calculate minimum values for PID, with e.g. France currently showing a minimum prevalence of 3·72 patients per 100 000 inhabitants. The most frequently documented permanent treatment is immunoglobulin replacement; 2819 patients (42% of all patients alive) currently receive this form of treatment.

Original languageEnglish
Pages (from-to)3-11
Number of pages9
JournalClinical and Experimental Immunology
Volume157
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Internet
Databases
Research
Common Variable Immunodeficiency
Therapeutics
Rare Diseases
Life Expectancy
France
Immunoglobulins
Immunoglobulin G
Guidelines
Incidence
Genes

Keywords

  • Epidemiology
  • ESID
  • Online database
  • Primary immunodeficiency
  • Registry

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Gathmann, B., Grimbacher, B., Beauté, J., Dudoit, Y., Mahlaoui, N., Fischer, A., ... Brodszki, N. (2009). The European internet-based patient and research database for primary immunodeficiencies: Results 2006-2008. Clinical and Experimental Immunology, 157(SUPPL. 1), 3-11. https://doi.org/10.1111/j.1365-2249.2009.03954.x

The European internet-based patient and research database for primary immunodeficiencies : Results 2006-2008. / Gathmann, B.; Grimbacher, B.; Beauté, J.; Dudoit, Y.; Mahlaoui, N.; Fischer, A.; Knerr, V.; Kindle, G.; Micol, R.; Benslama, L.; Plebani, A.; Notarangelo, L.; Pignata, C.; Bangs, C.; Lucas, M.; Tierney, P.; Core, C.; Dempster, J.; Exley, A.; Kumararatne, D.; Paschenko, O.; Kondratenko, I.; Shcherbina, Anna; Velbri, S.; Ciznar, P.; Duobiene, R.; Kilic, S.; Kütükcüler, N.; Sanal, Ö; Reisli, I.; Yegin, O.; Kanariou, M.; Papadopoulou-Alataki, E.; Trachana, M.; Hatzistilianou, M.; Farber, C. M.; Meyts, I.; Pasic, S.; Richter, D.; Máródi, L.; Touitou, I.; Abuzakouk, M.; Feighery, C.; Thon, V.; Litzman, J.; Cucuruz, M.; Wolska, B.; Szaflarska, A.; Reda, S.; Soler, P.; Caragol, I.; Llobet, P.; Savchak, I.; Marques, L.; Koren, A.; Hörnes, M.; Shchebet, S.; Goldacker, S.; Ritterbusch, H.; Faßhauer, M.; Sollinger, F.; Witte, T.; Baumann, U.; Wittkowski, H.; Viemann, D.; Niehues, T.; Stimm, H.; Brodszki, N.

In: Clinical and Experimental Immunology, Vol. 157, No. SUPPL. 1, 09.2009, p. 3-11.

Research output: Contribution to journalArticle

Gathmann, B, Grimbacher, B, Beauté, J, Dudoit, Y, Mahlaoui, N, Fischer, A, Knerr, V, Kindle, G, Micol, R, Benslama, L, Plebani, A, Notarangelo, L, Pignata, C, Bangs, C, Lucas, M, Tierney, P, Core, C, Dempster, J, Exley, A, Kumararatne, D, Paschenko, O, Kondratenko, I, Shcherbina, A, Velbri, S, Ciznar, P, Duobiene, R, Kilic, S, Kütükcüler, N, Sanal, Ö, Reisli, I, Yegin, O, Kanariou, M, Papadopoulou-Alataki, E, Trachana, M, Hatzistilianou, M, Farber, CM, Meyts, I, Pasic, S, Richter, D, Máródi, L, Touitou, I, Abuzakouk, M, Feighery, C, Thon, V, Litzman, J, Cucuruz, M, Wolska, B, Szaflarska, A, Reda, S, Soler, P, Caragol, I, Llobet, P, Savchak, I, Marques, L, Koren, A, Hörnes, M, Shchebet, S, Goldacker, S, Ritterbusch, H, Faßhauer, M, Sollinger, F, Witte, T, Baumann, U, Wittkowski, H, Viemann, D, Niehues, T, Stimm, H & Brodszki, N 2009, 'The European internet-based patient and research database for primary immunodeficiencies: Results 2006-2008', Clinical and Experimental Immunology, vol. 157, no. SUPPL. 1, pp. 3-11. https://doi.org/10.1111/j.1365-2249.2009.03954.x
Gathmann, B. ; Grimbacher, B. ; Beauté, J. ; Dudoit, Y. ; Mahlaoui, N. ; Fischer, A. ; Knerr, V. ; Kindle, G. ; Micol, R. ; Benslama, L. ; Plebani, A. ; Notarangelo, L. ; Pignata, C. ; Bangs, C. ; Lucas, M. ; Tierney, P. ; Core, C. ; Dempster, J. ; Exley, A. ; Kumararatne, D. ; Paschenko, O. ; Kondratenko, I. ; Shcherbina, Anna ; Velbri, S. ; Ciznar, P. ; Duobiene, R. ; Kilic, S. ; Kütükcüler, N. ; Sanal, Ö ; Reisli, I. ; Yegin, O. ; Kanariou, M. ; Papadopoulou-Alataki, E. ; Trachana, M. ; Hatzistilianou, M. ; Farber, C. M. ; Meyts, I. ; Pasic, S. ; Richter, D. ; Máródi, L. ; Touitou, I. ; Abuzakouk, M. ; Feighery, C. ; Thon, V. ; Litzman, J. ; Cucuruz, M. ; Wolska, B. ; Szaflarska, A. ; Reda, S. ; Soler, P. ; Caragol, I. ; Llobet, P. ; Savchak, I. ; Marques, L. ; Koren, A. ; Hörnes, M. ; Shchebet, S. ; Goldacker, S. ; Ritterbusch, H. ; Faßhauer, M. ; Sollinger, F. ; Witte, T. ; Baumann, U. ; Wittkowski, H. ; Viemann, D. ; Niehues, T. ; Stimm, H. ; Brodszki, N. / The European internet-based patient and research database for primary immunodeficiencies : Results 2006-2008. In: Clinical and Experimental Immunology. 2009 ; Vol. 157, No. SUPPL. 1. pp. 3-11.
@article{8dd4dcc0fa974d53be0df167e05c72cf,
title = "The European internet-based patient and research database for primary immunodeficiencies: Results 2006-2008",
abstract = "Summary Primary immunodeficiencies (PID) are rare diseases; therefore transnational studies are essential to maximize the scientific outcome and to improve diagnosis and therapy. In order to estimate the prevalence of PID in Europe as well as to establish and evaluate harmonized guidelines for the diagnosis and treatment of PID, the European Society for Immunodeficiencies (ESID) has developed an internet-based database for clinical and research data on patients with PID. This database is a platform for epidemiological analyses as well as the development of new diagnostic and therapeutic strategies and the identification of novel disease-associated genes. Within 4 years, 7430 patients from 39 countries have been documented in the ESID database. Common variable immunodeficiency (CVID) represents the most common entity, with 1540 patients or 20·7{\%} of all entries, followed by isolated immunoglobulin (Ig)G subclass deficiency (546 patients, 7·4{\%}). Evaluations show that the average life expectancy for PID patients varies from 1 to 49 years (median), depending on the type of PID. The prevalence and incidence of PID remains a key question to be answered. As the registration progress is far from finished we can only calculate minimum values for PID, with e.g. France currently showing a minimum prevalence of 3·72 patients per 100 000 inhabitants. The most frequently documented permanent treatment is immunoglobulin replacement; 2819 patients (42{\%} of all patients alive) currently receive this form of treatment.",
keywords = "Epidemiology, ESID, Online database, Primary immunodeficiency, Registry",
author = "B. Gathmann and B. Grimbacher and J. Beaut{\'e} and Y. Dudoit and N. Mahlaoui and A. Fischer and V. Knerr and G. Kindle and R. Micol and L. Benslama and A. Plebani and L. Notarangelo and C. Pignata and C. Bangs and M. Lucas and P. Tierney and C. Core and J. Dempster and A. Exley and D. Kumararatne and O. Paschenko and I. Kondratenko and Anna Shcherbina and S. Velbri and P. Ciznar and R. Duobiene and S. Kilic and N. K{\"u}t{\"u}kc{\"u}ler and {\"O} Sanal and I. Reisli and O. Yegin and M. Kanariou and E. Papadopoulou-Alataki and M. Trachana and M. Hatzistilianou and Farber, {C. M.} and I. Meyts and S. Pasic and D. Richter and L. M{\'a}r{\'o}di and I. Touitou and M. Abuzakouk and C. Feighery and V. Thon and J. Litzman and M. Cucuruz and B. Wolska and A. Szaflarska and S. Reda and P. Soler and I. Caragol and P. Llobet and I. Savchak and L. Marques and A. Koren and M. H{\"o}rnes and S. Shchebet and S. Goldacker and H. Ritterbusch and M. Fa{\ss}hauer and F. Sollinger and T. Witte and U. Baumann and H. Wittkowski and D. Viemann and T. Niehues and H. Stimm and N. Brodszki",
year = "2009",
month = "9",
doi = "10.1111/j.1365-2249.2009.03954.x",
language = "English",
volume = "157",
pages = "3--11",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The European internet-based patient and research database for primary immunodeficiencies

T2 - Results 2006-2008

AU - Gathmann, B.

AU - Grimbacher, B.

AU - Beauté, J.

AU - Dudoit, Y.

AU - Mahlaoui, N.

AU - Fischer, A.

AU - Knerr, V.

AU - Kindle, G.

AU - Micol, R.

AU - Benslama, L.

AU - Plebani, A.

AU - Notarangelo, L.

AU - Pignata, C.

AU - Bangs, C.

AU - Lucas, M.

AU - Tierney, P.

AU - Core, C.

AU - Dempster, J.

AU - Exley, A.

AU - Kumararatne, D.

AU - Paschenko, O.

AU - Kondratenko, I.

AU - Shcherbina, Anna

AU - Velbri, S.

AU - Ciznar, P.

AU - Duobiene, R.

AU - Kilic, S.

AU - Kütükcüler, N.

AU - Sanal, Ö

AU - Reisli, I.

AU - Yegin, O.

AU - Kanariou, M.

AU - Papadopoulou-Alataki, E.

AU - Trachana, M.

AU - Hatzistilianou, M.

AU - Farber, C. M.

AU - Meyts, I.

AU - Pasic, S.

AU - Richter, D.

AU - Máródi, L.

AU - Touitou, I.

AU - Abuzakouk, M.

AU - Feighery, C.

AU - Thon, V.

AU - Litzman, J.

AU - Cucuruz, M.

AU - Wolska, B.

AU - Szaflarska, A.

AU - Reda, S.

AU - Soler, P.

AU - Caragol, I.

AU - Llobet, P.

AU - Savchak, I.

AU - Marques, L.

AU - Koren, A.

AU - Hörnes, M.

AU - Shchebet, S.

AU - Goldacker, S.

AU - Ritterbusch, H.

AU - Faßhauer, M.

AU - Sollinger, F.

AU - Witte, T.

AU - Baumann, U.

AU - Wittkowski, H.

AU - Viemann, D.

AU - Niehues, T.

AU - Stimm, H.

AU - Brodszki, N.

PY - 2009/9

Y1 - 2009/9

N2 - Summary Primary immunodeficiencies (PID) are rare diseases; therefore transnational studies are essential to maximize the scientific outcome and to improve diagnosis and therapy. In order to estimate the prevalence of PID in Europe as well as to establish and evaluate harmonized guidelines for the diagnosis and treatment of PID, the European Society for Immunodeficiencies (ESID) has developed an internet-based database for clinical and research data on patients with PID. This database is a platform for epidemiological analyses as well as the development of new diagnostic and therapeutic strategies and the identification of novel disease-associated genes. Within 4 years, 7430 patients from 39 countries have been documented in the ESID database. Common variable immunodeficiency (CVID) represents the most common entity, with 1540 patients or 20·7% of all entries, followed by isolated immunoglobulin (Ig)G subclass deficiency (546 patients, 7·4%). Evaluations show that the average life expectancy for PID patients varies from 1 to 49 years (median), depending on the type of PID. The prevalence and incidence of PID remains a key question to be answered. As the registration progress is far from finished we can only calculate minimum values for PID, with e.g. France currently showing a minimum prevalence of 3·72 patients per 100 000 inhabitants. The most frequently documented permanent treatment is immunoglobulin replacement; 2819 patients (42% of all patients alive) currently receive this form of treatment.

AB - Summary Primary immunodeficiencies (PID) are rare diseases; therefore transnational studies are essential to maximize the scientific outcome and to improve diagnosis and therapy. In order to estimate the prevalence of PID in Europe as well as to establish and evaluate harmonized guidelines for the diagnosis and treatment of PID, the European Society for Immunodeficiencies (ESID) has developed an internet-based database for clinical and research data on patients with PID. This database is a platform for epidemiological analyses as well as the development of new diagnostic and therapeutic strategies and the identification of novel disease-associated genes. Within 4 years, 7430 patients from 39 countries have been documented in the ESID database. Common variable immunodeficiency (CVID) represents the most common entity, with 1540 patients or 20·7% of all entries, followed by isolated immunoglobulin (Ig)G subclass deficiency (546 patients, 7·4%). Evaluations show that the average life expectancy for PID patients varies from 1 to 49 years (median), depending on the type of PID. The prevalence and incidence of PID remains a key question to be answered. As the registration progress is far from finished we can only calculate minimum values for PID, with e.g. France currently showing a minimum prevalence of 3·72 patients per 100 000 inhabitants. The most frequently documented permanent treatment is immunoglobulin replacement; 2819 patients (42% of all patients alive) currently receive this form of treatment.

KW - Epidemiology

KW - ESID

KW - Online database

KW - Primary immunodeficiency

KW - Registry

UR - http://www.scopus.com/inward/record.url?scp=67149119008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67149119008&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2249.2009.03954.x

DO - 10.1111/j.1365-2249.2009.03954.x

M3 - Article

C2 - 19630863

AN - SCOPUS:67149119008

VL - 157

SP - 3

EP - 11

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - SUPPL. 1

ER -